Virion Therapeutics Reports Progress Towards HBV Functional Cure with Continued HBsAg Declines, Without Rebound, Up to Two Plus Years, After a Single VRON-0200 Dose, From its Phase 1b Study at EASL 2026

PHILADELPHIA--(BUSINESS WIRE)--Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the EASL Congress 2026 (The European Association for the Study of the Liver) in Barcelona, Spain, that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy for HBV Functional Cure, induced HBV-specific immune activation, restoration, and continued HBsAg declines, without